
La subida de precios de Mounjaro deja a los pacientes británicos con facturas elevadas
Peer reviewed by Dr Colin Tidy, MRCGPAuthored by Thomas Andrew Porteus, MBCSOriginally published 14 Aug 2025
Satisface las necesidades del paciente directrices editoriales
- DescargarDescargar
- Compartir
- Idioma
- Debate
If you buy the weight-loss medicine Mounjaro privately in the UK you may see a steep price increase from September. The change will not affect you if you get your medicine from the NHS.
Here we show what are the alternatives and what you need to think about if you change or stop taking medicines.
En este artículo:
Seguir leyendo
What is Mounjaro and who uses it?
Mounjaro is the brand name for tirzepatide, a medicine that mimics hormones in your body to help control blood sugar and reduce appetite. It’s given by weekly injection and is licensed for type 2 diabetes and for weight loss and weight management in adults aged 18 and over.
Mounjaro is authorised for adult patients with a BMI of 30 or more (obesity), as well as those with a BMI between 27-30 (overweight) who also have weight-related health problems such as prediabetes, high blood pressure, high cholesterol, or heart problems.
At the moment, more than 1.5 million people in the UK use weight-loss medicines. Mounjaro is the most popular. Around 9 out of 10 people getting it do so privately, often through online providers or high-street pharmacies.
What’s changing?
From September, the manufacturer Eli Lilly is putting up the price. The highest dose, which is one of the most commonly used, will increase from around £122 to £330 per month - a rise of around 170%. Lower doses will also cost more, but the increases will be smaller.
These changes only apply to people buying the drug privately and not those getting the medicine on the NHS. NHS prices are agreed in separate deals and will stay the same.
Seguir leyendo
Why is this happening?
Eli Lilly says the current private price in the UK was always temporary. The company initially set it low to help people access the drug earlier. Now that more research is available, and the drug has been launched in more countries, they say the UK price needs to match what other countries pay.
The manufacturer also said the price change was partly influenced by the global debate around medicine costs. In the US, President Donald Trump has suggested linking medicine prices to what’s paid in other countries. Eli Lilly says it supports fair pricing, but does not think that approach works in practice.
What are the alternatives?
Wegovy is a different injectable weight-loss medicine, made by Novo Nordisk. It works in a similar way and is also available on private prescription in the UK. Some people may find it easier to access or afford than Mounjaro, depending on the dose and provider.
Other options include tablets such as orlistat, as well as lifestyle support services offered by the NHS or local councils. Not all treatments work in the same way, and they’re not right for everyone, so it’s important to get proper advice.
Seguir leyendo
¿Qué debe hacer ahora?
If you’re using Mounjaro and worried about the cost, speak to your doctor or pharmacist. They can help you review your treatment and talk through other options.
Do not stop your injections suddenly without getting medical advice. A sudden stop can cause your blood sugar or appetite to change quickly, which might affect your health.
You can also ask about getting treatment through the NHS. Weight-loss medicines are only offered on the NHS in certain situations, but your doctor can explain whether you might qualify.
NHS England has announced that some people will now be able to get the Mounjaro jab from their doctor or at a local clinic.
This applies to people who have:
A BMI of 40 or above - or 37.5 if you are from a minority ethnic group.
Four out of five of the following health conditions - type 2 diabetes, high blood pressure, heart disease, high cholesterol, and sleep apnoea.
Patient picks

Noticias de salud
Flu season starts early: UKHSA urges eligible groups to get vaccinated
The UK Health Security Agency (UKHSA) is urging everyone eligible for a free flu vaccination to book their appointment as soon as possible, as flu activity continues to rise across England. The latest surveillance data show that this year’s flu season has started earlier than usual, with a sharp increase in cases among children and signs of growing spread in the wider community.
por Thomas Andrew Porteus, MBCS

Noticias de salud
Qué significa para usted el nuevo medicamento genérico para la diabetes y el corazón: dapagliflozin explicado
A major change to one of the NHS’s most widely used diabetes and heart medicines could save hundreds of millions of pounds and make proven treatments more accessible to thousands of patients across the UK. The change centres on dapagliflozin - a medicine used to treat type 2 diabetes, heart failure and certain kidney conditions. It belongs to a family of drugs called SGLT2 inhibitors - sometimes called 'flozins' - which have been described as one of the most important advances in diabetes and heart care in the last decade. Now that the medicine’s patent has been ruled invalid, generic dapagliflozin, identical in safety and effectiveness to the branded version, can be prescribed on the NHS at a much lower cost.
por Thomas Andrew Porteus, MBCS
Seguir leyendo
Historia del artículo
La información de esta página ha sido revisada por médicos cualificados.
Próxima revisión prevista: 14 de agosto 2025
14 agosto 2025 | Publicado originalmente
Autores:
Thomas Andrew Porteus, MBCSRevisado por expertos
Dr. Colin Tidy, MRCGP

Pregunte, comparta, conecte.
Explore debates, formule preguntas y comparta experiencias sobre cientos de temas de salud.

¿Se encuentra mal?
Evalúe sus síntomas en línea de forma gratuita
Suscríbase al boletín informativo para pacientes.
Tu dosis semanal de consejos de salud claros y fiables, redactados para ayudarte a sentirte informado, seguro y en control.
Al suscribirte, aceptas nuestra Política de privacidad. Puedes darte de baja en cualquier momento. Nunca vendemos tus datos.